Welcome to our dedicated page for PMGC Holdings news (Ticker: ELAB), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
PMGC Holdings Inc. reports news across a holding-company portfolio that includes precision manufacturing, aerospace and defense supply-chain operations, industrial packaging, defense technology, and bioscience subsidiaries. Recurring company updates cover subsidiary long-term supply agreements, ITAR and aerospace quality standards, customer relationships, manufacturing capacity, and capital actions tied to acquisition-led platform development.
PMGC news also covers NorthStrive Biosciences patent filings and manufacturing work for engineered probiotic assets such as EL-22 and EL-32, as well as Pacific Sun Packaging activity in electronics and IT hardware packaging markets. Defense technology announcements describe subsidiary initiatives involving autonomous systems, counter-drone applications, and GPS-denied navigation environments.
PMGC Holdings (Nasdaq: ELAB) filed its Q1 2026 Form 10-Q and reported strong balance sheet expansion driven by financing and M&A, including the SVM Machining acquisition.
Total assets reached ~$26.0M, up 102% from year-end 2025. Shareholders’ equity rose to ~$12.6M and cash to ~$14.4M, the Company’s largest cash balance. Q1 2026 revenue was ~$682,000, exceeding full-year 2025 revenue and up ~124% sequentially.
Subsequent events include forming NorthStrive Defense Tech, a new $40M equity purchase facility with an institutional investor, and closing the acquisition of A&B Aerospace, a cash-flow-positive aerospace manufacturer with ~$4.5M trailing-twelve-month revenue.
PMGC Holdings (NASDAQ: ELAB) acquired 100% of A&B Aerospace, a California-based AS9100D and ISO 9001:2015 certified precision machining and aerospace manufacturing company serving Tier 1 customers such as Boeing, Honeywell, and Moog.
A&B generated about $5.0M TTM revenue and $610K management-adjusted EBITDA as of February 28, 2026. The cash-free, debt-free base purchase price is $4.5M, including $4.275M paid at closing and a $225K indemnification holdback. This is PMGC’s fifth precision manufacturing acquisition in 12 months, advancing its U.S. aerospace and defense roll-up strategy.
NorthStrive Biosciences (Nasdaq: ELAB) filed U.S. Patent Application No. 19/655,160 covering pharmaceutical formulations, dosing regimens, and method‑of‑use claims for EL-22, a myostatin‑engineered probiotic targeting muscle‑wasting conditions.
The claims span multiple indications including GLP‑1 receptor agonist–associated muscle loss, sarcopenia, muscle disuse atrophy, and certain neurological disorders, and the filing is positioned to expand the company’s layered intellectual property around EL-22.
NorthStrive Biosciences (Nasdaq: ELAB) filed U.S. Patent Application No. 19/655,160 to expand its EL-22 myostatin-engineered probiotic into human pharmaceutical uses.
The application covers formulated pharmaceutical products, specific dosing regimens and formulations for a broad range of muscle-wasting conditions including sarcopenia, disuse atrophy and certain neurological disorders, and notes potential use alongside GLP-1 weight-loss treatments. The filing aims to strengthen NorthStrive's intellectual property portfolio for muscle-preservation therapeutics.
NorthStrive Defense Tech (NASDAQ: ELAB) announced on April 23, 2026 an exclusive option agreement to license U.S. Patent No. 12,277,716 B2, a patented visual-inertial cooperative navigation system for drones operating in GPS-jammed, spoofed, and denied environments.
The option covers exclusive patent rights in the aerospace and defense field plus a non-exclusive know-how license; the company will evaluate the technology during a defined period and may negotiate a definitive license if it exercises the option. No guarantee of a final license or successful commercialization was given.
PMGC Holdings (Nasdaq: ELAB) subsidiary SVM Machining signed a Long-Term Agreement with Turbo-Jet Products to supply mission-critical aerospace and defense components.
The LTA has an initial five-year term with annual renewal provisions, forms a purchasing framework for future orders, and follows SVM's ITAR registration on March 20, 2026.
PMGC Holdings (Nasdaq: ELAB) announced a $40 million equity purchase facility with an institutional investor on April 17, 2026, with approximately $10 million expected at first closing. The facility provides a 24-month commitment period and permits draws at PMGC's discretion, supporting an accelerated M&A roll-up focused on aerospace, defense, and industrial precision manufacturing.
PMGC has completed four acquisitions over the past 12 months and targets ITAR-registered, AS9100D-certified precision CNC machining businesses, plus opportunistic cash-flow positive targets outside aerospace and defense.
NorthStrive Biosciences (NASDAQ: ELAB) announced on April 13, 2026 the U.S. transfer of its EL-32 Working Cell Bank (WCB) to a third-party fermentation facility and the start of a manufacturing optimization program to raise yield and enable scalable, cost-efficient production.
EL-32 is a dual-action engineered probiotic targeting myostatin and activin-A pathways to help preserve lean muscle during GLP-1 therapy. Collaboration with Modulant Biosciences covers process development for animal-health products while NorthStrive retains human therapeutic rights, aiming to support IND-enabling activities and future GMP manufacturing.
Pacific Sun Packaging (NASDAQ: ELAB) will exhibit at ITAD Europe 2026 on April 15–16, 2026 in Nice, France, marking an expansion of its international presence.
The company will present protective packaging for high-value IT hardware at Booth #414, targeting global buyers, recyclers, and enterprise decision-makers across the ITAD and circular electronics supply chain.
AGA Precision Systems (Nasdaq: ELAB) executed a second long-term agreement on April 9, 2026, with a globally recognized Tier 1 aerospace and defense customer to supply precision CNC-manufactured components for multi-year programs. The LTA formalizes future purchase orders and includes defined performance commitments for quality, delivery, and pricing.
AGA said the agreement reinforces its qualified-supplier status, supports recurring revenue potential, and increases operational visibility while the customer identity remains confidential due to ITAR and regulatory obligations.